File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Live-donor liver transplantation for hepatocellular carcinoma

TitleLive-donor liver transplantation for hepatocellular carcinoma
Authors
KeywordsHepatocellular carcinoma
Live-donor liver transplantation
Recurrence
Issue Date2007
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.wiley.com/WileyCDA/WileyTitle/productCd-HEPR.html
Citation
The 4th Single Topic Conference on HCC, Awaji Island, Japan, 2–3 December 2005. In Hepatology Research, 2007, v. 37 n. Suppl 2, p. S275-S276 How to Cite?
AbstractLive-donor liver transplantation (LDLT) is a valuable option for patients with hepatocellular carcinoma (HCC) because compared with deceased-donor liver transplantation (DDLT), the tumor could be eradicated early. However, a higher incidence of recurrence is observed when the result is compared with DDLT. The difference is explained by the timing of transplant because only patients with slow HCC growth (and probably less aggressive tumors) can wait for DDLT. Nevertheless, arecent survey of results of LDLT for HCC in Asia indicated that the 3-year survival rate is approximately 60-80%, which is better than that of any treatment modalities for inoperable HCC associated with poor liver function. LDLT for HCC is still worthwhile to pursue and deserves further evaluation.
Persistent Identifierhttp://hdl.handle.net/10722/83563
ISSN
2015 Impact Factor: 2.208
2015 SCImago Journal Rankings: 0.782
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-06T08:42:31Z-
dc.date.available2010-09-06T08:42:31Z-
dc.date.issued2007en_HK
dc.identifier.citationThe 4th Single Topic Conference on HCC, Awaji Island, Japan, 2–3 December 2005. In Hepatology Research, 2007, v. 37 n. Suppl 2, p. S275-S276en_HK
dc.identifier.issn1386-6346en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83563-
dc.description.abstractLive-donor liver transplantation (LDLT) is a valuable option for patients with hepatocellular carcinoma (HCC) because compared with deceased-donor liver transplantation (DDLT), the tumor could be eradicated early. However, a higher incidence of recurrence is observed when the result is compared with DDLT. The difference is explained by the timing of transplant because only patients with slow HCC growth (and probably less aggressive tumors) can wait for DDLT. Nevertheless, arecent survey of results of LDLT for HCC in Asia indicated that the 3-year survival rate is approximately 60-80%, which is better than that of any treatment modalities for inoperable HCC associated with poor liver function. LDLT for HCC is still worthwhile to pursue and deserves further evaluation.-
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.wiley.com/WileyCDA/WileyTitle/productCd-HEPR.htmlen_HK
dc.relation.ispartofHepatology Researchen_HK
dc.rightsHepatology Research. Copyright © Blackwell Publishing Ltd.en_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectHepatocellular carcinoma-
dc.subjectLive-donor liver transplantation-
dc.subjectRecurrence-
dc.titleLive-donor liver transplantation for hepatocellular carcinomaen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1872-034X.2007.00196.x-
dc.identifier.pmid17877494-
dc.identifier.hkuros140963en_HK
dc.identifier.volume37-
dc.identifier.spageS275-
dc.identifier.epageS276-
dc.identifier.isiWOS:000250758400030-
dc.publisher.placeIreland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats